SA
XERS icon

Sanctuary Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Sanctuary Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33,429
Closed -$58.5K – 2674
2024
Q2 		$58.5K Buy
+33,429
New +$67.4K ﹤0.01% 2292

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sanctuary Advisors's XERS Position: Q3 2024 in Review

Sanctuary Advisors sold out of Xeris Biopharma Holdings (XERS) in Q3 2024, closing a stake of 33,429 shares — an estimated $58.5K sold.

Sanctuary Advisors first reported a position in XERS in Q2 2024 and held it in 1 quarter. The position peaked at $58.5K in Q2 2024. 144 funds tracked by Wall St. Rank hold XERS as of Q3 2024.

  • Sanctuary Advisors reported no remaining Xeris Biopharma Holdings position as of Q3 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 33,429 Xeris Biopharma Holdings shares in Q3 2024, an estimated $58.5K.
  • Sanctuary Advisors first reported a position in Xeris Biopharma Holdings in Q2 2024 and held it in 1 quarter.
  • Sanctuary Advisors's Xeris Biopharma Holdings position peaked at $58.5K in Q2 2024.
  • 144 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2024.

Based on Sanctuary Advisors's 13F filing for Q3 2024, filed 25 Nov 2024.